La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Travere Therapeutics a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Travere Therapeutics..

Travere Therapeutics (NASDAQ:TVTX) Azioni, Catena delle Opzioni

TRAVERE THERAPEUTICS INC

Travere Therapeutics

Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.

Travere Therapeutics, Inc. - Common Stock

Travere Therapeutics Inc

U.S. stocks traded mixed midway through trading, with the Dow Jones index dipping more than 150 points on Tuesday.
The Dow traded down 0.35% to 44,249.09 while the NASDAQ gained 0.07% to 20,427.63. The S&amp;P 500 also fell, dropping, 0.03% to 6,228.39.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/short-ideas/25/07/46296650/top-2-industrials-stocks-you-may-want-to-dump-this-quarter">Top 2 Industrials Stocks You May Want To Dump This Quarter</a>
Leading and Lagging Sectors Energy shares jumped by 2.1% on Tuesday.
In trading on Tuesday, utilities stocks dipped by 1.9%.
Top Headline
The US Manheim Used Vehicle Value Index increased 1.6% month-over-month for June, following a 1.4% decline in May.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul class="wp-block-list">
<li>ENDRA Life Sciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDRA#NASDAQ">NDRA</a>) shares shot up 134% to $8.10 after the company announced it will be granted a US patent titled &#8220;Radio Frequency Applicator&#8221;.</li>
<li>Shares of ProKidney Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PROK#NASDAQ">PROK</a>) got a boost, surging 218% to $1.95 after the company reported statistically and clinically significant topline results from its Phase 2 REGEN-007 trial evaluating Rilparencel in patients with chronic kidney disease and diabetes.</li>
<li>Humacyte, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUMA#NASDAQ">HUMA</a>) shares were also up, gaining 20% to $2.5750. Humacyte announced Symvess has been awarded Electronic Catalog Listing approval from the US Defense Logistics Agency.</li>
</ul>
Equities Trading DOWN
<ul class="wp-block-list">
<li>Blue Gold Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BGL#NASDAQ">BGL</a>) shares dropped 21% to $58.75. Blue Gold announced the formation of its inaugural Advisory Board for Blockchain Evolution and named T. Jack Williams as the first member of the Advisory Board.</li>
<li>Shares of Sunrun Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUN#NASDAQ">RUN</a>) were down 11% to $9.84. Solar stocks dropped on Tuesday after President Donald Trump signed an executive order to fast-track the end of clean-energy tax credits late Monday. Keybanc analyst Sophie Karp upgraded Sunrun from Underweight to Sector Weight.</li>
<li>Apogee Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APGE#NASDAQ">APGE</a>) was down, falling 8% to $36.24. Apogee Therapeutics recently released 16-week data from Part A of the Phase 2 APEX clinical trial of APG777 for moderate-to-severe atopic dermatitis.</li>
</ul>
Commodities In commodity news, oil traded up 0.3% to $68.14 while gold traded down 1.1% at $3,306.90.
Silver traded down 0.8% to $36.625 on Tuesday, while copper fell 0.5% to $5.0000.
Euro zone
European shares were higher today. The eurozone's STOXX 600 rose 0.40%, while Spain's IBEX 35 Index rose 0.10%. London's FTSE 100 gained 0.46%, Germany's DAX 40 gained 0.68% and France's CAC 40 gained 0.46% during the session.
Asia Pacific Markets
Asian markets closed higher on Tuesday, with Japan's Nikkei gaining 0.26%, Hong Kong's Hang Seng climbing 1.09%, China's Shanghai Composite gaining 0.70% and India's BSE Sensex gaining 0.32%.
Economics
<ul class="wp-block-list">
<li>The US Manheim Used Vehicle Value Index increased 1.6% month-over-month for June, following a 1.4% decline in May.</li>
<li>The NFIB Small Business Optimism Index fell to 98.6 in June from 98.8 in May and compared to market estimates of 98.7.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/25/07/46296955/meta-platforms-to-rally-around-9-here-are-10-top-analyst-forecasts-for-tuesday">Meta Platforms To Rally Around 9%? Here Are 10 Top Analyst Forecasts For Tuesday</a> </li>
</ul>
Photo via Shutterstock

Equities

News

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

APGE

HUMA

NDRA

PROK

Gold Falls 1%; ProKidney Shares Spike Higher

The Hershey Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HSY#NYSE">HSY</a>) announced on Tuesday that Kirk Tanner will take over as President and CEO, beginning August 18, marking a significant leadership transition for the company.
Tanner, a seasoned executive in the food and beverage sector, succeeds Michele Buck, who is retiring after a transformative tenure. Buck will remain with the company for a period in an advisory role to support a smooth leadership transition.
The leadership change follows a detailed succession plan, positioning Hershey for sustained growth and innovation under new guidance.
Also Read: <a href="https://www.benzinga.com/25/04/44643347/hershey-expands-snack-empire-with-acquisition-of-lesserevil-for-750m" target="_blank" rel="noreferrer noopener">Hershey Bites Into Better-For-You Snacking With LesserEvil Deal: Details</a>
Tanner currently serves as CEO of The Wendy&#8217;s Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WEN#NASDAQ">WEN</a>), where he prioritized brand growth and international expansion. He will depart the <a href="https://www.benzinga.com/pressreleases/25/07/n46294385/wendys-appoints-ken-cook-as-interim-ceo" target="_blank" rel="noreferrer noopener">fast-food chain on July 18, 2025</a>. Wendy&#8217;s CFO Ken Cook has been appointed as interim CEO while the company searches for a permanent replacement.
Tanner also brings more than 30 years of experience from PepsiCo Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEP#NASDAQ">PEP</a>), where he most recently led the $28 billion North American beverage division.
He also held several senior positions, including President of Global Foodservice and VP of Sales for the UK and Ireland. Hershey&#8217;s Board praised Tanner as a strong operator with deep experience in snack foods, beverages, and innovation.
Chair of the CEO Search Committee Mary Kay Haben highlighted Tanner&#8217;s balanced leadership and strategic vision as ideal for driving the company forward. She also thanked Buck for her impactful leadership and for building Hershey&#8217;s status as a multi-category snacking powerhouse.
In a statement, Tanner expressed enthusiasm for leading Hershey, saying the opportunity was &#8220;once-in-a-lifetime.&#8221; He emphasized his commitment to consumers, partners, and employees. Buck also voiced confidence in Tanner, calling it a privilege to support the transition after leading the company through years of sustained growth.
Price Action: HSY shares are trading lower by 2.98% to $170.32&nbsp;at last check Tuesday, while WEN shares are trading lower by 0.13% to $11.29.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/general/restaurants/25/05/45202730/wendys-mixes-weak-sales-with-a-side-of-resilience-fast-food-restaurant-has-solid-marketing-menu-innovation-plans-says-analyst" target="_blank" rel="noreferrer noopener">Wendy&#8217;s Mixes Weak Sales With A Side Of Resilience: Fast-Food Restaurant Has &#8216;Solid Marketing,&#8217; Menu Innovation Plans, Says Analyst</a></li>
</ul>
Photo via Shutterstock

Topics

Movers

General

Hershey Taps PepsiCo And Wendy's Veteran Kirk Tanner As Next CEO

Oppenheimer analyst Jay Olson maintains Praxis Precision Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRAX#NASDAQ">PRAX</a>) with a Outperform and raises the price target from $97 to $115.

Price Target

Analyst Ratings

PRAX

Oppenheimer Maintains Outperform on Praxis Precision Medicine, Raises Price Target to $115

WIIM

SCCO

Shares of copper stocks are trading higher after President Trump said he believes copper tariffs will be 50%.

Oppenheimer analyst Chad Larkin maintains Lyft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYFT#NASDAQ">LYFT</a>) with a Outperform and raises the price target from $17 to $20.

LYFT

Oppenheimer Maintains Outperform on Lyft, Raises Price Target to $20

Oppenheimer analyst Ian Zaffino maintains Kyndryl Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KD#NYSE">KD</a>) with a Outperform and raises the price target from $47 to $55.

Oppenheimer Maintains Outperform on Kyndryl Hldgs, Raises Price Target to $55

Oppenheimer analyst Owen Lau maintains Fair Isaac (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FICO#NYSE">FICO</a>) with a Outperform and raises the price target from $2293 to $2300.

FICO

Oppenheimer Maintains Outperform on Fair Isaac, Raises Price Target to $2300

<a href="https://www.youtube.com/live/vL6PaBTA4I8">https://www.youtube.com/live/vL6PaBTA4I8</a>

Politics

President Trump Says We Are Thinking Of Taking Over Governance Of Washington D.C.; Says "Not Getting Involved" In NYC Mayoral Race

Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) stock may be down 20% year-to-date in 2025, but that's not stopping analysts and investors, including Ark Invest to bet on the company's future success thanks to robotaxis, less expensive electric vehicles and <a href="https://www.benzinga.com/markets/penny-stocks/23/08/34102486/exclusive-cathie-wood-tells-benzinga-why-tesla-should-trade-as-a-tech-stock">other future catalysts.</a>
Here&#8217;s a look at Ark Invest CEO&nbsp;Cathie Wood&#8217;s&nbsp;future price targets for Tesla and how investors could still benefit if she is right about the EV leader again.
Following Wood Into Tesla:&nbsp;Wood&nbsp;<a href="https://www.benzinga.com/news/21/01/19082834/with-tesla-over-800-arks-catherine-wood-proves-doubters-wrong-on-huge-bullish-call-from-2018" target="_blank" rel="noreferrer noopener">famously called a bullish&nbsp;</a>price target of $4,000 on Tesla in 2018 that came true (split-adjusted) years later. While many were skeptical of Wood&#8217;s high price target at the time, her conviction paid off and helped cement her status in the financial community.
Wood&nbsp;announced a&nbsp;$2,600 price target for Tesla in<a href="https://www.benzinga.com/etfs/specialty-etfs/24/06/39294523/cathie-wood-ark-invest-set-new-2-600-price-target-for-tesla-every-car-becomes-an-ai-powered-c" target="_blank" rel="noreferrer noopener">&nbsp;June 2024</a>, raising the bar from a previous price target of $2,000 for the electric vehicle stock.
Ark Invest has a price target of $2,600 for Tesla by the year 2029, with a bear case price target of $2,000 and a bull case of $3,100.
With Tesla shares trading at $301.98 today, an investor could purchase 3.31 shares with a $1,000 investment
Here's a look at how much the $1,000 could be worth in 2029 if Wood's various price targets come true:
<ul class="wp-block-list">
<li>$2,000 Bear Case: $6,602, +560.2%</li>
<li>$2,600 Base Case: $8,606, +760.6%</li>
<li>$3,100 Bull Case: $10,261, +926.1%</li>
</ul>
Each of the price targets from Wood would gain 560% or more, representing huge returns over the next five years.
Keep in mind that the average return of the S&amp;P 500 Index is around 10.5% annually since the fund's 1957 inception. The price target from Wood would mark a sizable outperformance to historical stock index returns.
Are you buying when the CEOs of the Magnificent 7 are selling?
<ul class="wp-block-list">
<li>Stay in the know with our Insider Trades page — <a href="https://www.benzinga.com/sec/insider-trades/">see when leaders like Mark Zuckerberg, Elon Musk, and Jensen Huang are offloading their own shares.</a></li>
</ul>
Why It's Important:&nbsp;Wood reiterated her $2,600 price target for Tesla <a href="https://www.benzinga.com/news/large-cap/25/03/44537429/cathie-wood-doubles-down-on-2600-tesla-stock-price-prediction">earlier this year</a> in several interviews. The fund manager said robotaxis represents a software-as-a-service-like business model that will provide high operating margins for Tesla.
The new price target is based on several factors, with the majority of the price target coming from Tesla's robotaxi ambitions.
"ARK estimates that nearly 90% of Tesla's enterprise value and earnings will be attributed to the robotaxi business in 2029," the open-source model reads.
Aside from the new price targets in the thousands of dollars, Ark also lists a price target of $350 for Tesla if it eliminates the robotaxi network from the model, stressing the importance of this future catalyst.
The new price target forecast model breaks down Tesla's 2029 revenue as 63% from robotaxis and 26% from electric vehicles, with the rest coming from items such as insurance and energy storage.
Ark Invest estimates that Tesla could have revenue of $1.2 trillion in 2029 and EBITDA of $440 billion. The prediction assumes that Tesla will sell 5.8 million electric vehicles in 2029.
"Tesla plans to unveil its dedicated robotaxi vehicle in August 2024. While Tesla could transform its current fleet into robotaxis, we believe a custom-built CyberCab reflects increased confidence that its autonomy software will allow Tesla to scale the robotaxi business."
The new Ark Invest price target does not include any impact from the Tesla Semi, Tesla Supercharging network, FSD licensing or AI-As-A-Service. The price model includes minimal results from the Optimus bot.
"(Tesla's) business model should transform from one-off vehicle sales to a recurring revenue base as every car becomes an AI-powered cash flow generation machine."
Wood's new price targets would take Tesla to a market capitalization of between $7 trillion and $10.9 trillion and the title of the world's most valuable company.
Tesla CEO&nbsp;Elon Musk&nbsp;recently highlighted&nbsp;<a href="https://www.benzinga.com/news/24/06/39324085/elon-musk-thanks-shareholders-says-tesla-starting-a-new-book-could-hit-30-trillion-valuation-hot-d-i" target="_blank" rel="noreferrer noopener">the potential value&nbsp;</a>of the robotaxi business and Optimus bot as the catalysts that could make Tesla the most valuable company in the world, worth north of $30 trillion.
Many laughed at Wood when she made her bullish $4,000 price prediction. Years later, the stock was north of that level on a split-adjusted value. Wood continues to bet heavily on Tesla with the Ark Innovation ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#BATS">ARKK</a>), Ark Next Generation ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKW#BATS">ARKW</a>) and Ark Autonomous Technology &amp; Robotics ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKQ#BATS">ARKQ</a>) <a href="https://www.ark-funds.com/" target="_blank" rel="noreferrer noopener">counting </a>
Tesla is the top holding in ARKK and ARKQ at 9.14% and 9.94% of assets, respectively. In ARKW, Tesla is the fourth-largest holding at 6.18% of assets at the time of writing.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/general/space/25/05/45680115/tesla-the-best-elon-musk-company-84-say-no-these-3-rank-higher">Tesla The Best Elon Musk Company? 84% Say No — These 3 Rank Higher</a></li>
</ul>
This article was previously published by Benzinga and has been updated.

Long Ideas

Education

ARKK

ARKQ

ARKW

TSLA

Here's How Much $1,000 Invested In Tesla Stock Today Will Be Worth If Cathie Wood's Price Prediction Comes True In 2029

Oppenheimer analyst Bryan Blair maintains SPX Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPXC#NYSE">SPXC</a>) with a Outperform and raises the price target from $170 to $197.

SPXC

Oppenheimer Maintains Outperform on SPX Technologies, Raises Price Target to $197

Citigroup analyst Patrick Cunningham maintains Olin (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OLN#NYSE">OLN</a>) with a Buy and lowers the price target from $26 to $25.

Citigroup Maintains Buy on Olin, Lowers Price Target to $25

CRCL

CRCL stock has given up its prior loss. Circle Internet Group shares were trading lower after Mizuho initiated coverage on the stock with an Underperform rating and announced a price target of $85.

President Trump Says Will Take Two Years To Build It; Will Have Contract Probably Over Next Couple Of Months

Citigroup analyst Patrick Cunningham maintains Dow (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOW#NYSE">DOW</a>) with a Neutral and lowers the price target from $30 to $28.

Citigroup Maintains Neutral on Dow, Lowers Price Target to $28

Roth Capital analyst Matt Koranda reiterates Kits Eyecare (TSX:<a class="ticker" href="https://www.benzinga.com/stock/KITS#TSX">KITS</a>) with a Buy and maintains C$22 price target.

Reiteration

TSX:KITS

Roth Capital Reiterates Buy on Kits Eyecare, Maintains C$22 Price Target

President Trump Says Want To Have One Company For Air Traffic Control Modernization; Raytheon, IBM Will Bid

Citigroup analyst Ronald Josey maintains Carvana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVNA#NYSE">CVNA</a>) with a Buy and raises the price target from $325 to $415.

CVNA

Citigroup Maintains Buy on Carvana, Raises Price Target to $415

In a significant legal challenge that could reshape the future of <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">public health policy</a> in the United States, a powerful alliance of leading medical and public health organizations, including the American Academy of Pediatrics (AAP), the American College of Physicians (ACP), and the American Public Health Association (APHA), filed a lawsuit on Monday against Secretary of Health and Human Services Robert F. Kennedy Jr.
The plaintiffs contend that Secretary Kennedy has launched an &#8220;assault on science, public health, and evidence-based medicine&#8221; through unilateral and arbitrary changes to COVID-19 vaccine recommendations for children and pregnant individuals.
This unprecedented <a target="_blank" href="https://www.aap.org/en/news-room/news-releases/aap/2025/leading-medical-professional-societies-patients-sue-hhs-robert-f-kennedy-jr-for-unlawful-unilateral-vaccine-changes/?_gl=1&#x2A;12sk5li&#x2A;_ga&#x2A;NTIxOTQ2NTgyLjE3NTE5NzQ2MjA.&#x2A;_ga_FD9D3XZVQQ&#x2A;czE3NTE5NzQ2MTkkbzEkZzEkdDE3NTE5NzQ2MjYkajUzJGwwJGgw" rel="noreferrer noopener">legal action</a> seeks to halt what the coalition describes as an &#8220;existential threat to vaccination in America,&#8221; arguing that Kennedy&#8217;s directives, including the controversial dismissal of expert advisors from the CDC&#8217;s immunization committee, are endangering the nation&#8217;s long-standing, science-based vaccine infrastructure and, critically, the health of its most vulnerable populations.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/25/07/46256464/lawmakers-investigate-whether-pfizer-delayed-covid-19-vaccine-results-for-political-reasons" rel="noreferrer noopener">Lawmakers Investigate Whether Pfizer Delayed COVID-19 Vaccine Results For Political Reasons</a>
<h2 class="wp-block-heading">Lawsuit Details And Allegations</h2>
The comprehensive lawsuit, filed in the U.S. District Court for the District of Massachusetts, names the U.S. Department of Health and Human Services (HHS) and Secretary Robert F. Kennedy Jr. as defendants. The plaintiffs, which also include the Infectious Diseases Society of America (IDSA), the Massachusetts Public Health Alliance (MPHA), the Society for Maternal-Fetal Medicine (SMFM), and a pregnant physician, assert that Kennedy acted &#8220;arbitrarily and capriciously&#8221; by altering COVID-19 vaccine recommendations for children and pregnant people without scientific basis.
This follows Secretary Kennedy&#8217;s public statement in May, where he <a target="_blank" href="https://www.benzinga.com/25/05/45624037/robert-f-kennedy-jr-says-cdc-drops-covid-vaccine-for-healthy-pregnant-women-kids" rel="noreferrer noopener">expressed pleasure at the removal</a> of the COVID-19 vaccine for healthy children and pregnant women from CDC recommended immunization schedules.
A critical aspect of the lawsuit&#8217;s complaint is Secretary Kennedy&#8217;s alleged unjust dismissal of 17 members of the Centers for Disease Control and Prevention&#8217;s (CDC) Advisory Committee on Immunization Practices (ACIP). These experts were reportedly replaced with individuals known for espousing anti-vaccine viewpoints.
Dr. Susan J. Kressly, President of the AAP, underscored the gravity of these actions, stating, &#8220;This wasn&#8217;t just sidelining science. It&#8217;s an attack on the very foundation of how we protect families and children&#8217;s health. And the consequences could be dangerous.&#8221;
The lawsuit further details a pattern of interference, including blocked CDC communications, delayed or canceled meetings of CDC and Food and Drug Administration (FDA) vaccine advisers, and the announcement of studies to investigate non-existent links between vaccines and autism.
<h2 class="wp-block-heading">Seeking Injunctions And Protecting Public Health</h2>
The plaintiffs are seeking both preliminary and permanent injunctions to reverse Secretary Kennedy&#8217;s rescissions of COVID-19 vaccine recommendations. They also request a declaratory judgment to legally pronounce these changes as unlawful. Richard H. Hughes IV, lead counsel for the plaintiffs and partner at Epstein Becker Green, voiced grave concerns, asserting, &#8220;This administration is an existential threat to vaccination in America, and those in charge are only just getting started. If left unchecked, Secretary Kennedy will accomplish his goal of ridding the United States of vaccines, which would unleash a wave of preventable harm on our nation&#8217;s children.&#8221;
The lawsuit alleges that the Directive is but one example of the Secretary&#8217;s agenda to dismantle the long-standing, Congressionally-authorized, science- and evidence-based vaccine infrastructure that has prevented the deaths of untold millions of Americans. The filing highlights that the Secretary&#8217;s dismantling of the vaccine infrastructure must end, and halting this effort begins with vacating the Directive.
<h2 class="wp-block-heading">FDA&#8217;s Internal Disagreements And Historical Legal Actions</h2>
Per a recent media report, Dr. Vinay Prasad, the U.S. Food and Drug Administration&#8217;s (FDA) top vaccine official, overruled agency scientists to limit approval of two COVID-19 vaccines, despite internal recommendations to clear <a target="_blank" href="https://www.benzinga.com/news/health-care/25/07/46250723/rfk-jr-influence-evident-as-vaccine-chief-overrules-scientists-limits-covid-19-vaccine-approval" rel="noreferrer noopener">them for broader use</a>.
FDA scientists had recommended full approval for updated COVID vaccines from Novavax Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) and Moderna Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) for individuals aged 12 and older, citing favorable risk-benefit analyses.
But Prasad restricted the shots to those at higher risk, seniors and people with underlying health conditions, arguing that declining hospitalization and death rates from COVID-19 shifted the balance of risks and benefits.
While distinct from the HHS lawsuit, this report underscores a broader climate of scrutiny and debate surrounding vaccine policy.
The AAP has a history of pursuing legal action against the federal government, regardless of political affiliation. Past instances include a 1983 lawsuit against HHS regarding life-sustaining treatment for infants and separate lawsuits against the FDA in 2016 and 2018 concerning graphic warnings on cigarettes and e-cigarette regulation, respectively.
Price Action: MRNA stock is trading higher by 11% to $33.18, and NVAX stock is up 6.61% at $7.05 at last check Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46301475/coreweaves-9-billion-bet-turns-crypto-miner-into-ai-powerhouse" target="_blank" rel="noreferrer noopener">CoreWeave&#8217;s $9 Billion Bet Turns Crypto Miner Into AI Powerhouse</a></li>
</ul>
Photo by lev radin via Shutterstock

Biotech

Government

Health Care

Legal

MRNA

NVAX

Medical Groups Sue RFK Jr. For Assault On Science Over Unlawful COVID-19 Vaccine Rollbacks

Citigroup analyst Christopher Allen maintains Cboe Global Markets (BATS:<a class="ticker" href="https://www.benzinga.com/stock/CBOE#BATS">CBOE</a>) with a Neutral and raises the price target from $230 to $245.

CBOE

Citigroup Maintains Neutral on Cboe Global Markets, Raises Price Target to $245

Roth Capital analyst Darren Aftahi downgrades Core Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORZ#NASDAQ">CORZ</a>) from Buy to Neutral and maintains the price target from $20 to $20.

Downgrades

Core Scientific, Inc. - Class A Common Stock

Comments

Travere Therapeutics

Travere Therapeutics (TVTX) Opzioni

Travere Therapeutics (NASDAQ:TVTX) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO